Skip to main content

Phase 1/2 long-term data showed tividenofusp alfa significantly reduced central and peripheral biomarkers to near-normal levels while improving liver volume, hearing thresholds, adaptive behavior, and cognition in most participants.:

Source: Neurology Read More